Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852104 | 0.91 | KMT2A (0.50) | SMN1; SMN2MAPK1TSHRFABP4LMNA | |
| SCHEMBL4022476 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPK1TSHRFABP4LMNA | |
| SCHEMBL1857604 | 0.87 | CASR (0.40) | SMN1; SMN2TSHRLMNAMAPTAKR1C3 | |
| SCHEMBL4024326 | 0.86 | MAPK1 (0.46) | SMN1; SMN2MAPK1TSHRLMNAALDH1A1 | |
| SCHEMBL1854510 | 0.83 | LPAR1 (0.45) | AKR1C3 | |
| SCHEMBL25737609 | 0.82 | CNR1 (0.37) | SMN1; SMN2TSHRLMNAMAPTTBXA2R | |
| SCHEMBL4018016 | 0.81 | PTGES (0.37) | TSHRLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL4021417 | 0.81 | LIMK2 (0.39) | SMN1; SMN2TSHRLMNAMAPTALDH1A1 | |
| SCHEMBL4021244 | 0.81 | HDAC4 (0.45) | MAPK1ALDH1A1 | |
| SCHEMBL1856431 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPK1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | claimed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | SMN1; SMN2 2147/4885MAPK1 2747/4885TSHR 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.